Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Comparative effectiveness of chemotherapy in elderly patients with metastatic colorectal cancer.

Satram-Hoang S, Lee L, Yu S, Guduru SR, Gunuganti AR, Reyes C, McKenna E.

J Gastrointest Cancer. 2013 Mar;44(1):79-88. doi: 10.1007/s12029-012-9450-x.

2.

The effect of DNA mismatch repair (MMR) status on oxaliplatin-based first-line chemotherapy as in recurrent or metastatic colon cancer.

Kim ST, Lee J, Park SH, Park JO, Lim HY, Kang WK, Kim JY, Kim YH, Chang DK, Rhee PL, Kim DS, Yun H, Cho YB, Kim HC, Yun SH, Chun HK, Lee WY, Park YS.

Med Oncol. 2010 Dec;27(4):1277-85. doi: 10.1007/s12032-009-9374-x. Epub 2009 Dec 1.

PMID:
19949897
3.

Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II).

Hoff PM, Hochhaus A, Pestalozzi BC, Tebbutt NC, Li J, Kim TW, Koynov KD, Kurteva G, Pintér T, Cheng Y, van Eyll B, Pike L, Fielding A, Robertson JD, Saunders MP.

J Clin Oncol. 2012 Oct 10;30(29):3596-603. doi: 10.1200/JCO.2012.42.6031. Epub 2012 Sep 10.

PMID:
22965965
4.

Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group.

Porschen R, Arkenau HT, Kubicka S, Greil R, Seufferlein T, Freier W, Kretzschmar A, Graeven U, Grothey A, Hinke A, Schmiegel W, Schmoll HJ; AIO Colorectal Study Group.

J Clin Oncol. 2007 Sep 20;25(27):4217-23. Epub 2007 Jun 4.

PMID:
17548840
5.

Retrospective comparison of CAPOX and FOLFOX dose intensity, toxicity, and clinical outcomes in the treatment of metastatic colon cancer.

Loree JM, Mulder KE, Ghosh S, Spratlin JL.

J Gastrointest Cancer. 2014 Jun;45(2):154-60. doi: 10.1007/s12029-013-9574-7.

PMID:
24408272
6.

Oxaliplatin in combination with 5-fluorouracil/leucovorin or capecitabine in elderly patients with metastatic colorectal cancer.

Arkenau HT, Graeven U, Kubicka S, Grothey A, Englisch-Fritz C, Kretzschmar A, Greil R, Freier W, Seufferlein T, Hinke A, Schmoll HJ, Schmiegel W, Porschen R; AIO Colorectal Study Group.

Clin Colorectal Cancer. 2008 Jan;7(1):60-4.

PMID:
18279579
7.

CAPOX associated with toxicities of higher grade but improved disease-free survival when compared with FOLFOX in the adjuvant treatment of stage III colon cancer.

Loree JM, Mulder KE, Ghosh S, Spratlin JL.

Clin Colorectal Cancer. 2014 Sep;13(3):172-7. doi: 10.1016/j.clcc.2014.01.001. Epub 2014 Feb 6.

PMID:
24630275
8.

Patients with locally advanced and metastatic colorectal cancer treated with capecitabine versus 5-fluorouracil as monotherapy or combination therapy with oxaliplatin: a cost comparison.

Chu E, Schulman KL, McKenna EF Jr, Cartwright T.

Clin Colorectal Cancer. 2010 Oct;9(4):229-37. doi: 10.3816/CCC.2010.n.034.

PMID:
20920995
9.

Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma.

Twelves C, Boyer M, Findlay M, Cassidy J, Weitzel C, Barker C, Osterwalder B, Jamieson C, Hieke K; Xeloda Colorectal Cancer Study Group.

Eur J Cancer. 2001 Mar;37(5):597-604.

PMID:
11290435
10.

XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer.

Cassidy J, Tabernero J, Twelves C, Brunet R, Butts C, Conroy T, Debraud F, Figer A, Grossmann J, Sawada N, Schöffski P, Sobrero A, Van Cutsem E, Díaz-Rubio E.

J Clin Oncol. 2004 Jun 1;22(11):2084-91.

PMID:
15169795
11.

Comparative effectiveness of 5-fluorouracil with and without oxaliplatin in the treatment of colorectal cancer in clinical practice.

Healey E, Stillfried GE, Eckermann S, Dawber JP, Clingan PR, Ranson M.

Anticancer Res. 2013 Mar;33(3):1053-60.

PMID:
23482781
12.

Cost effectiveness analysis of pharmacokinetically-guided 5-fluorouracil in FOLFOX chemotherapy for metastatic colorectal cancer.

Goldstein DA, Chen Q, Ayer T, Howard DH, Lipscomb J, Harvey RD, El-Rayes BF, Flowers CR.

Clin Colorectal Cancer. 2014 Dec;13(4):219-25. doi: 10.1016/j.clcc.2014.09.007. Epub 2014 Sep 21.

PMID:
25306485
13.

Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: post hoc analysis of a large phase II study.

Twelves CJ, Butts CA, Cassidy J, Conroy T, Braud Fd, Diaz-Rubio E, Tabernero JM, Schoffski P, Figer A, Brunet R, Grossmann J, Sobrero AF, Van Cutsem EJ.

Clin Colorectal Cancer. 2005 Jul;5(2):101-7.

PMID:
16098250
14.

Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials.

Van Cutsem E, Hoff PM, Harper P, Bukowski RM, Cunningham D, Dufour P, Graeven U, Lokich J, Madajewicz S, Maroun JA, Marshall JL, Mitchell EP, Perez-Manga G, Rougier P, Schmiegel W, Schoelmerich J, Sobrero A, Schilsky RL.

Br J Cancer. 2004 Mar 22;90(6):1190-7.

15.

Severe sequence-specific toxicity when capecitabine is given after Fluorouracil and leucovorin.

Hennig IM, Naik JD, Brown S, Szubert A, Anthoney DA, Jackson DP, Melcher AM, Crawford SM, Bradley C, Brown JM, Seymour MT.

J Clin Oncol. 2008 Jul 10;26(20):3411-7. doi: 10.1200/JCO.2007.15.9426.

PMID:
18612156
16.

Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.

Cassidy J, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzén F, Saltz L.

J Clin Oncol. 2008 Apr 20;26(12):2006-12. doi: 10.1200/JCO.2007.14.9898.

PMID:
18421053
17.

Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a phase II, proof-of-concept study.

Capitain O, Asevoaia A, Boisdron-Celle M, Poirier AL, Morel A, Gamelin E.

Clin Colorectal Cancer. 2012 Dec;11(4):263-7. doi: 10.1016/j.clcc.2012.05.004. Epub 2012 Jun 9.

PMID:
22683364
18.

Capecitabine plus oxaliplatin for the treatment of colorectal cancer.

Carrato A, Gallego-Plazas J, Guillén-Ponce C.

Expert Rev Anticancer Ther. 2008 Feb;8(2):161-74. doi: 10.1586/14737140.8.2.161. Review.

PMID:
18279056
19.

Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials.

Arkenau HT, Arnold D, Cassidy J, Diaz-Rubio E, Douillard JY, Hochster H, Martoni A, Grothey A, Hinke A, Schmiegel W, Schmoll HJ, Porschen R.

J Clin Oncol. 2008 Dec 20;26(36):5910-7. doi: 10.1200/JCO.2008.16.7759. Epub 2008 Nov 17. Erratum in: J Clin Oncol. 2009 Dec 1;27(34):5859.

PMID:
19018087
20.

Safety and effectiveness of oxaliplatin-based chemotherapy regimens in adults 75 years and older with colorectal cancer.

McCleary NJ, Odejide O, Szymonifka J, Ryan D, Hezel A, Meyerhardt JA.

Clin Colorectal Cancer. 2013 Mar;12(1):62-9. doi: 10.1016/j.clcc.2012.09.001. Epub 2012 Oct 24.

Supplemental Content

Support Center